Acknowledged medical writing support
Addiction medicine
Alho H, et al. Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. Int J Drug Policy 2020; 76:102616.
Kakko J, et al. Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice. Front Psychiatry 2019; 10:592.
Autoimmune diseases
Taylor PC, et al. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med 2021; 10(3):509.
Hercogová J, et al. AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis. Br J Dermatol 2020; 182:316-26.
Baumgart DC, et al. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol 2019; 10:279.
Edwards CJ, et al. Switching to Biosimilars: Current Perspectives in Immune-Mediated Inflammatory Diseases. Expert Opin Biol Ther 2019; 19:1001-14.
HEOR
Klein H and Boleckova J. Resource utilization and procedure-related costs associated with transfemoral transcatheter aortic valve replacement. J Med Econ 2017; 20:640-45.
Infectious diseases
Welte et al. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. Future Microbiol 2021; Online ahead of print.
Bosheva M, et al. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients. Pediatr Infect Dis 2021; 40:e222-9.
Hamed K, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiol 2020; 15:35-48.
Hamed K, et al. No evidence for ceftobiprole-induced immune hemolytic anemia in three Phase 3 clinical trials. Infect Drug Resist 2020; 13:3461.
Overcash JS, et al. Ceftobiprole Compared with Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-Blind Trial (TARGET). Clin Infect Dis 2020. Online ahead of print.
Stemler J, et al. Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. Mycoses 2020; 63:1060-68.
Pulmonary hypertension
Chin KM, et al. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Insights From the Phase III GRIPHON Study. Circulation 2019; 139:2440-50.
Torbicki A, et al. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circ Cardiovasc Qual Outcomes 2019; 12:e005095.
Berger RMF, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017; 83:1734-44.
Publications as an author
Hinchliffe E, Carter S, et al. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 15:913-914.
Carter S, et al. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012; 49:570-9.
Hock AK, Vigneron A, Carter S, et al. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J 2011; 30:4921-30.
Stindt MH, Carter S, et al. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 2011; 10:3176-88.
Carter S and Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19:18-24.
Carter S and Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008; 7:2519-28.
Carter S and Vousden KH. A role for Numb in p53 stabilization. Genome Biol 2008; 9:221.
Carter S, et al. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biol 2007; 9:428-35.
Carter S, et al. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 2004; 279:52835-9.
Hammond DE, Carter S, et al. Met receptor dynamics and signalling. Curr Top Microbiol Immunol 2004; 286:21-44.
Hammond DE, Carter S, et al. Endosomal dynamics of Met determine signaling output. Mol Biol Cell 2003; 14: 1346-54.
